Day-long Subcutaneous Infusion of Exenatide Lowers Glycemia in Patients with Type 2 Diabetes
The DOI matches its Crossref record.
Abstract
Exenatide (exendin-4) is an incretin mimetic with potential antidiabetic activity. This study examined the effects of a continuous subcutaneous (SC) infusion of exenatide (0.2, 0.4, 0.6, or 0.8 microg/kg/day) or placebo (PBO) on glycemic control over 23 h intervals. Twelve subjects with type 2 diabetes treated with metformin and/or diet received 10 infusions (4 exenatide, 6 PBO) on consecutive days. Exenatide was given in a dose-increasing design with at least one placebo infusion between each exenatide infusion, and with meals and a snack provided during the first 14 h of infusion. Plasma exenatide concentrations were dose-proportional. Plasma glucose (4-23 h) was lower in all exenatide arms compared to placebo (p<0.0001). The change in insulin/glucagon ratio and amylin concentrations from pre-infusion to post-infusion was increased (p<0.005, p<0.05, respectively) in the combined exenatide arms, but remained unchanged in the placebo groups. Nausea and vomiting were the most common treatment emergent adverse events. Exenatide infusion also appeared to have positive effects on beta-cell and alpha-cell function as measured by proinsulin/insulin ratios and mean glucagon concentrations. In summary, exenatide lowered plasma glucose during both prandial and fasting states when delivered as a continuous SC infusion over twenty-three hours, suggesting that exenatide can provide day-long glycemic control in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 446
Self-citationDunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262
“However, the mean plasma exenatide level in this study was 4 times as high as that reported as the minimal effective concentration in humans, about 50 pg/mL (68).”
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
“The doses regarding exendin‐4 were selected based on previous data in other animal experiments and clinical trials.((17,18))”
MethodVlasakakis, G., Johnson, S. L., Lin, J., Yao, X., Gruenloh, C. J., Chism, J. P., & Nunez, D. J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0222-4 · Cited by 2
Metadata
- Authors
- Taylor, K., Kim, D., Nielsen, L. L., Aisporna, M., Baron, A. D., & Fineman, M. S.
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2005-10
- Volume
- 37
- Issue
- 10
- Pages
- 627-632
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W2092171219
- Cited by
- 38
- References
- 0
- FWCI
- 2.01
- Type
- journal article
- Language
- de
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Day-long Subcutaneous Infusion of Exenatide Lowers Glycemia in Patients with Type 2 Diabetes. https://app.cochat.ai/papers/10.1055/s-2005-870529
- The paper
- Taylor, K., Kim, D., Nielsen, L. L., Aisporna, M., Baron, A. D., & Fineman, M. S. (2005). Day-long Subcutaneous Infusion of Exenatide Lowers Glycemia in Patients with Type 2 Diabetes. Hormone and Metabolic Research. https://doi.org/10.1055/s-2005-870529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.